But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
Valuations in some large-caps are compelling over the long term.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
Despite the good action in the indices, I'm not putting much money to work.
It feels like there is some squeeze action taking place now.
Does UNH need to see the primary care doctor?

3 Small Biotech Value Plays Real Money Pro($)

These stocks will be great stories in the second half of 2017, and are significantly undervalued.
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

3 Post-Earnings Biotech Buys Real Money Pro($)

These names are now undervalued, despite solid results and good fundamentals.
The price momentum and money flow indicators of the drug maker are in positive alignment.

Columnist Conversations

View Chart »  View in New Window » View Chart » 


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.